These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 15571213

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N.
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, Zuo X, Liu Y, Li Z, Li X, Zhu P, Li J, Zhang Z, Huang A, Zhang Y, Bao C.
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [Abstract] [Full Text] [Related]

  • 11. Febuxostat (Teijin/Ipsen/TAP).
    Tomlinson B.
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1168-78. PubMed ID: 16312139
    [Abstract] [Full Text] [Related]

  • 12. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
    Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, MacDonald P, Joseph-Ridge N.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
    [Abstract] [Full Text] [Related]

  • 13. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL, Barrons R, Veverka A, Snider KM.
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [Abstract] [Full Text] [Related]

  • 14. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Febuxostat for prevention of gout attacks.
    Pohar S, Murphy G.
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW.
    N Engl J Med; 2005 Dec 08; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.